Semaglutide compound is a glucagon-like peptide-1 (GLP-1) receptor agonist formulated for weight management and glycemic control. As a synthetic analog of human GLP-1, it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and promotes satiety—mechanisms that together reduce fasting and postprandial glucose and support sustained weight loss. Administered by subcutaneous injection (and available in oral formulations), semaglutide demonstrates robust efficacy in lowering HbA1c and producing clinically meaningful reductions in body weight across multiple dose regimens.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes and weight management. Engineered as a long-acting once-weekly injectable peptide, tirzepatide enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite—producing robust improvements in glycemic control and clinically meaningful weight loss. Clinical trials have demonstrated superior reductions in HbA1c and body weight compared with existing GLP-1 receptor agonists, along with favorable effects on cardiovascular risk markers and metabolic parameters.